摘要
目的:观察急性脑梗死患者应用尼莫地平进行脑保护的治疗效果。方法:将60例急性脑梗死患者随机均分为尼莫地平组和对照组,于治疗前和治疗后第14、30天采用Barthel指数(BI)量表评价;并于治疗前和治疗后第3、7天测血清基质金属蛋白酶9(MMP-9)水平。结果:治疗后第14、30天尼莫地平组和对照组BI评分分别为(67.98±12.67)分vs(.89.02±10.37)分,(60.06±11.89)分vs(.78.83±13.02)分,2组比较差异有统计学意义(P<0.05或P<0.01);治疗后第3、7天尼莫地平组和对照组血清MMP-9浓度分别为(238.73±123.37)mg·mL-1vs(.86.23±29.45)mg·mL-1,(299.83±119.47)mg·mL-1vs(.105.56±31.17)mg·mL-1,2组比较差异有统计学意义(P<0.05或P<0.01)。结论:尼莫地平治疗急性脑梗死患者可有效地改善急性缺血性脑损害患者的神经功能缺损,疗效较好。
OBJECTIVE：To discuss cerebral protection efficacy of nimodipine for the patients with acute cerebral infarction.METHODS：60 acute cerebral infarction patients were divided into nimodipine group（30 cases）and control group（30 cases）.The BI measuring scales were used for evaluation before treatment and on the 14th and 30th day after treatment.The level of plasma MMP-9 was detected before treatment and on the 3th and 7th day after treatment.RESLUTS：After treatment 14 and 30 days,measuring scale of BI of nimodipine group and control group were（67.98±12.67）point vs.（89.02±10.37）point,（60.06±11.89）point vs.（78.83±13.02）point.Compared with control group,the change was more significant（P0.05 or P0.01）.After treatment 3 and 7 days,The level of MMP-9 of nimodipine group and control group were（238.73±123.37）mg·L-1 vs.（86.23± 29.45）mg·L-1,（299.83±119.47）mg·L-1 vs.（105.56±31.17）mg·L-1.There was significant difference between 2 groups（P0.05 or P0.01）.CONCLUSION：Nimodipine could effectively improve the nerve function handicap for the patients with acute cerebral infarction and have good efficacy.
出处
《中国药房》
CAS
CSCD
2012年第16期1490-1492,共3页
China Pharmacy
关键词
急性脑梗死
尼莫地平
脑保护
基质金属蛋白酶9
Acute cerebral infarction
Nimodipine
Neuroprotection
Matrix metal protease 9
